Skip to content
Menu

Insight Molecular Diagnostics Enrolls First Several Patients In Its GALACTIC Study Evaluating GraftAssure Molecular Test For Monitoring Rejection In Kidney Transplant Recipients

Benzinga Newsdesk 16 hours ago

News

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

This study serves to introduce GraftAssure technology to new transplant centers and additionally builds validation data ahead of potential FDA authorization of GraftAssureDx, a kitted version of the company’s clinical assay.

iMDx seeks to deliver a best-in-class molecular diagnostic test kit, to expand and improve testing access for kidney transplant patients, which it anticipates will deliver new value in the estimated $3 billion addressable market for regulated transplant rejection testing.

 

Read at benzinga.com

← All stock news